Published 2 days ago • loading... • Updated 2 days ago

Rigel Announces Poster Presentations at the 2025 ASCO Annual Meeting and EHA2025 Congress

Rigel Pharmaceuticals announced seven poster presentations at the 2025 ASCO Annual Meeting and EHA2025 Congress focusing on GAVRETO and REZLIDHIA data.
These presentations follow clinical trials that evaluated GAVRETO for RET fusion-positive NSCLC and other tumors, and REZLIDHIA for relapsed/refractory mIDH1 AML patients.
GAVRETO showed a 70.3% overall response rate with a median duration of response of 19.1 months, while REZLIDHIA demonstrated activity including a 50% ORR and manageable safety profiles.
In clinical trials of REZLIDHIA in relapsed or refractory AML patients, 16% experienced differentiation syndrome, which was fatal in 1% of cases, while hepatotoxicity was reported in 23% of patients and typically resolved within approximately 12 days.
These results support REZLIDHIA’s potential benefit in earlier treatment lines for AML and reaffirm GAVRETO's durable efficacy in RET fusion-positive cancers amid manageable risks.

Insights by Ground AI

Does this summary seem wrong?

33 Articles

All

Left

Center

Right

The Billings Gazette

+32 Reposted by 32 other sources

Center

Rigel Announces Poster Presentations at the 2025 ASCO Annual Meeting and EHA2025 Congress

Final data from the GAVRETO® (pralsetinib) Phase 1/2 ARROW study in RET fusion-positive NSCLC and other solid tumors Supportive data for REZLIDHIA® (olutasidenib) utilization in patients with mIDH1 R/R AML

2 days ago·Billings, United States

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year